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Abstract
Background: The current method to determine the efficacy of chemoprevention in TRAMP mouse model of
carcinoma of prostate (CaP) is by extracting and weighing the prostate at different time points or by
immunohistochemistry analysis. Non-invasive determination of volumes of prostate glands and seminal vesicles
before, during and after treatment would be valuable in investigating the efficacy of newer chemopreventive
agents in CaP. The purpose of this study was to determine whether in vivo magnetic resonance imaging (MRI)
using a 3 tesla clinical MRI system can be used to follow the effect of chemoprevention in TRAMP model of
mouse CaP.
Methods: Mice were randomized into control and treated groups. The animals in treated group received 10 µmol/kg
of CDDO, 5 days a week for 20 weeks. Animals underwent in vivo MRI of prostate gland and seminal vesicles by a
clinical 3 Tesla MRI system just before (at 5 weeks), during and at the end of treatment, at 25 weeks. T1-weighted and
fat saturation (FATSAT) multiecho fast spin echo T2- weighted images (T2WI) were acquired. Volume of the prostate
glands and seminal vesicles was determined from MR images. T2 signal intensity changes in the seminal vesicles
were determined by subtracting higher echo time (TE) from lower TE T2WI. Following treatments all animals were
sacrificed, prostate and seminal vesicles collected, and the tissues prepared for histological staining. All data were
expressed as mean ± 1 standard deviation. Two-way or multivariate analysis of variance followed by post-hoc test
was applied to determine the significant differences. A p-value of <0.05 was considered significant.
Results: Histological analysis indicated tumor in 100% of control mice, whereas 10% of the treated mice showed
tumor in prostate gland. Both MRI and measured prostate weights showed higher volume/weight in control mouse
group. MRI showed significantly higher volume of seminal vesicles in control animals and T2 signal intensity changes
in seminal vesicles of control mice indicating higher number of tumor foci, which was also proven by histology.
Conclusions: In vivo MRI is helpful in determining the efficacy of chemoprevention of prostate cancer in TRAMP
mice.
Background
According to American Cancer Society, prostate cancer
is the most frequently diagnosed malignant neoplasm
among men in America and is the second leading can-
cer in deaths. The American Cancer Society estimates
that there will be 240,890 new cases of prostate cancer
diagnosed and 33,720 prostate cancer specific deaths in
2011. To help solve and find a remedy for this illness,
investigators in the field of prostate cancer therapy and
research are using a mouse model called TRAMP
(Transgenic Adenocarcinoma of Mouse Prostate).
TRAMP is a transgenic mouse model of carcinoma of
prostate (CaP). The mouse model has the ability to
develop spontaneous tumors, which have helped study
chemopreventive treatment efficacy. This model helps to
predict therapeutic responses in different chemopreven-
tive treatment strategies.
Because of the long latency period and slow progres-
sion of the preneoplastic lesions to the malignant stage,
CaP is ideally suited for developing primary, secondary
and tertiary preventive strategies. Thus, intervention
with plant-derived polyphenolic compounds or their
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preventing/delaying the incidence, progression, recur-
rence, morbidity and mortality associated with cancer of
the prostate. Triterpenes or triterpenoids are members
of a larger family of structurally related compounds
known as cyclosqualenoids that are widely distributed in
the plant kingdom [1]. Oleanolic acid and ursolic acid
are naturally occurring triterpenoids that have been
used in traditional medicine as anti-cancer and anti-
inflammatory agents [2-4]. 2-cyano-3,12-dioxooleana-1,9
(11)-dien-28-oic acid (CDDO) has also shown chemo-
preventive activity in animal models of liver, breast and
lung cancer [5-7], but they have not been investigated
for the prevention of prostate cancer.
The current method to determine the efficacy of treat-
ments is by extracting and weighing the prostate at dif-
ferent time points or by immunohistochemistry analysis.
Non-invasive determination of prostate glands and semi-
nal vesicles volumes before, during and after treatment
will be valuable in investigating the efficacy of different
newer chemopreventive agents in prostate cancer. Mag-
netic resonance imagining (MRI) is often used to ana-
lyze therapeutic efficacy in pre-clinical studies [8,9].
Only few investigators have successfully viewed the
images of the mouse prostate glands and its tumor by
high-resolution magnetic resonance imaging [10-12].
MRI is thought to be one of the best choices among in
vivo imaging modalities, not only because of its high
resolution but also due to its ability to separate tissues
based on signal intensities. Unlike human, prostate
gland in mouse has different anatomy and does not
remain fixed. Mouse prostate is multi-lobed (two ante-
rior, two dorsolateral and one ventral), which surrounds
urethra and moves along with urinary bladder. More-
over, tumor in TRAMP model does not remain confined
within prostate lobes and spreads in seminal vesicles
[11,13,14]. Therefore, lobes of the prostate as well as
seminal vesicles should be analyzed by in vivo imaging
to determine the effects of chemoprevention. The pur-
pose of this paper is to determine whether non-invasive
in vivo MRI can determine the effects of treatment in
TRAMP model of mouse CaP.
Methods
Ethical Statement
Animal experiments described in the manuscript were
approved by our animal care and user committee at
Henry Ford Health System (protocol number 856)
according to the guideline and policies of office of
laboratory animal welfare (OLAW) and public health
service, National Institutes of Health. All the experi-
ments were performed according to the approved
protocol.
Reagents
CDDO was obtained from the National Cancer Institute,
Bethesda, MD through the Rapid Access to Intervention
Development Program
Mice
T R A M Pm i c ew e r eb r e db yt h eJ a c k s o nL a b o r a t o r i e s
(Bar Harbor, ME, USA) through their Speed Expansion
Service involving in vitro fertilization of C57BL/6
females with C57BL/6-Tg (TRAMP) 8247NG/J males.
Mice were genotyped for the transgene (Tag) and deliv-
ered to us when 4 weeks old. Mice were maintained in
temperature-controlled room (68-72°F) with a 12 h
light/dark cycle and provided semi-purified AIN-76A
mouse chow and water ad libitum. Mice were accli-
mated for one week before starting the experiment. All
animal treatments were according to the protocol
approved by the Institutional Animal Care and Use
Committee [15].
Treatment protocol
At the age of 5 weeks, 50 male TRAMP mice were
weighed and randomized into two groups: Mice in vehi-
cle control group (n = 25) were administered 0.1 ml of
vehicle consisting of cremophor-EL:DMSO:PBS (1:1:8), 5
days a week for 20 weeks by p.o. gavage. In the treat-
ment group (n = 25), mice were administered CDDO at
a dose of 10 μmol/kg in 0.1 ml of vehicle, 5 days a week
for 20 weeks. Body weight of control and CDDO-treated
mice was recorded each week and mice were observed
for treatment related stress, such as water and food
withdrawal, unusual posture, ruffled fur or listlessness.
Ten randomly selected animals from each group under-
went in vivo MRI of prostate glands and seminal vesi-
cles, just before (5 weeks of age), in the middle (at 12
weeks of age) and at the end of treatment. Same
selected animals under went MRI at all time points,
however, identity of individual animal was not tracked
during imaging or at euthanasia due to loss of body
markings or ear tags during the long treatment. At the
age of 25 wk following MRI, mice from both groups
were sacrificed 24 h after the last administration of vehi-
cle or CDDO. After opening the abdomen, mice were
visually observed for the presence of tumor mass, enlar-
gement of seminal vesicles, prostate lobes, and pelvic
lymph nodes. Urogenital tract and pelvic lymph nodes
were removed and weighed. Tissue samples were pro-
cessed for histological analyses.
In Vivo MRI Studies by 3 Tesla
An appropriate state of anesthesia was obtained with
isoflurane (3% for induction, 0.7% to 1.5% for mainte-
nance mixed with O2). MRI was obtained with a 3
Arbab et al. BMC Medical Imaging 2011, 11:21
http://www.biomedcentral.com/1471-2342/11/21
Page 2 of 11Tesla clinical MRI system (Signa Excite, GE health)
u s i n g5 0m md i a m e t e r×1 0 8m mR Fr u n gl e n g t hs m a l l
animal imaging coil (Litzcage small animal imaging sys-
tem, Doty Scientific Inc, Columbia, SC). After position-
ing using a triplanar FLASH sequence, T1, and fast spin
echo (FSE) fat suppression (FATSAT) T2-weighted
images were obtained. T1- weighted images were
obtained using following sequence; TR/TE = 300/10 ms,
128 × 128 matrix, 13-15 slices, 0.9 mm thick, 40 mm
field of view (FOV), number of excitation (NEX) = 2-4.
Fast spin echo T2-weighted images were obtained using
standard two-dimensional Fourier transformation
(2DFT) multislice (13-15) multiecho (2 echoes) MRI. A
series of 2 sets of images (13-15 slices for each set) were
obtained using TEs of 11 to 70 msec and a TR of 4000-
5000 ms. The images were acquired using 40 mm FOV,
1 mm slice thickness, 128 × 128 matrix, and NEX = 2.
We used clinical 3T MRI system due to availability of
small animal coil synchronized with 3T MRI and opti-
mized for small animal scanning. Moreover, all the
available clinically approved MRI sequences can be
used, especially fat suppression during T1 and T2-
weighted images. Easy sequence manipulation and
shorter acquisition time were also considered as
advantages.
Image analysis
All images were analyzed using our home made image
analysis software “Eigentool” (http://www.radiologyre-
search.org/eigentool.htm). Volume of the prostate glands
and seminal vesicles were determined by an investigator
blinded to the assignment of animals (treated vs con-
trol). The investigators were trained to indentify the
prostate glands and the seminal vesicles by going
through both axial and coronal images obtained with
T1W and T2W sequences. Irregular region of interests
(ROIs) were drawn over prostate and seminal vesicles
separately and the areas were recorded (Figure 1). All
the image sections that contained prostate and seminal
vesicles were included in the analysis. Total calculated
areas were multiplied by image thickness to determine
the volume of prostate and seminal vesicles. The values
were expressed in cm
3. The volume of prostate gland
calculated from MRI images was compared with the
weight of the prostate gland (gm) determined at
necropsy. MRI could detect dorsal and anterior/ventral
lobes of the prostate gland clearly. However, due to par-
tial volume effect the lateral lobes that continue with
coagulating gland could not be separated from sur-
rounding tissues and seminal vesicles. On the other
hand, ex vivo extracted prostate glands comprised of all
the lobes. It is expected that due to differential density
between control (due to tumors) and treated animals
the volume measured by MRI will not exactly match the
weight of the extracted prostate glands and seminal
vesicles.
Analysis of signal intensity
According to Dr. Bradley (http://www.e-radiography.net/
mrict/fund mr2/fundmri 2.htm) mathematically the
intensity (I) of the spin echo signal can be approxi-
mated:
I = N(H)f(v)(1 - e -T R / T 1)e -T E / T 2
where N(H) is the NMR-visible, mobile proton density
and f(v) is an unspecified function of flow. This equation
indicates that the intensity of the MR signal increases as
hydrogen density and T2 increase and as T1 decreases.
It should also be noted that T1 and T2 influences are
both subject to TR (repetition time) and TE (echo time).
Thus, the effect of the T1 and T2 relaxation times of
the substance on signal intensity is subject to the speci-
fic values of TR and TE selected before the image is
acquired. When considered in the most simplistic terms,
the spin echo is a two-step process. The first step (long-
itudinal recovery) determines the starting intensity for
the second step (transverse decay). The starting intensity
reflects the relationship between T1 and TR and is ulti-
mately limited by the proton density. The subsequent
decay from this starting intensity reflects the relation-
ship between T2 and TE. As the TR is prolonged, all
substances eventually recover full longitudinal magneti-
zation between repetitions and the pixel intensity
becomes dependent only upon proton density and is
independent of T1. Substances with longer T2 times
will generate stronger signals than substances with
shorter T2 times, if both are acquired at the same TE
and if proton density and T1 are comparable. Increasing
the echo delay time (TE) increases the differences in the
T2 decay curves between substances, increasing the T2-
weighting. Images obtained with a sufficiently long TR
and TE will cause fluid (such as CSF) or edema more
intense than solid tissue (such as brain).
It is expected that multiple small tumor foci and asso-
ciated edema will cause lengthening of T2 values in semi-
nal vesicles of control untreated animals compared to that
of treated animals, therefore, signal intensity on T2-
weighted images will vary based on the echo delay time
(TE). The TR used in image acquisition is long enough to
recover full longitudinal magnetization between repeti-
tions and the signal intensity on MR images with different
TE will be different between areas of normal seminal vesi-
cle and in areas of tumor growths due to varying T2
values. We expect that tissues with higher T2 will show
relatively high signal intensity on images obtained with
higher TE and subtraction of the images of higher TE
from lower TE will give differential image. To calculate
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(70 ms) were subtracted from corresponding images with
lower TE (11 ms) and the resultant images were analyzed.
The same investigator blinded to the assignment of
animals drew ROIs on the left and right seminal vesicles
(to include all areas of seminal vesicles in all sections) and
on the skeletal muscles of the corresponding left and right
thighs (Figure 2). Average signal intensities of seminal
Figure 1 Prostate gland and seminal vesicles on MR images. Identification of prostate gland (areas inside white dots) and seminal vesicles
(areas inside black dots) on fat saturation T2-weighted images. Volume of the prostate gland and seminal vesicles was determined by drawing
irregular region of interest. B = urinary bladder, T = testes and SV = seminal vesicle.
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nal intensity of thigh muscles. It is to be cautioned that
inflammation or abscess in seminal vesicles may give simi-
lar signal intensity changes, however, TRAMP model cre-
ates spontaneous small tumor foci in the seminal vesicles,
and inflammation or abscess is not expected.
Histological analysis
Tissue specimens of prostate gland and seminal vesicles
for all animals that underwent MRI were fixed in 10%
neutral buffered formalin for 48 h and then embedded in
paraffin. Five to six micrometers thick sections were cut
and stained with H&E for routine histology. Tumors were
graded according to our published method in prostate
glands in all control and treated animals [16] that under-
went MRI by using photomicrographs from 5 randomly
selected areas. Presence or absence of tumor foci in semi-
nal vesicles was also checked and photomicrographed. For
dorso-lateral prostate (DLP), histopathological classifica-
tion was as follows; normal DLP (ducts lined with single
layer of secretory epithelial cells surrounded by 2-3 cell
layers of fibromuscular stroma); low-grade prostatic
intraepithelial neoplasia (PIN) (epithelial cells with variably
elongated nuclei with condensed chromatin); high-grade
PIN (epithelial stratification and tufting, presence of
micropapillary and cribiform structures); well differen-
tiated (WD) carcinoma (epithelial cells invading fibromus-
cular stroma) and moderately (MD) to poorly
differentiated (PD) adenocarcinoma of the prostate (sheets
of neoplastic cells with little or no glandular structures).
Data analysis
All data were expressed as mean ± one standard devia-
tion. Either two way analysis of variance (ANOVA) or
multivariate ANOVA followed by post-hoc test Fisher’s
PLSD was applied to determine the significant differ-
ences between treated and control or among different
time points (5 weeks, 12 weeks and 25 weeks). A p-
value of <0.05 was considered significant.
Results
Treatment with CDDO is well tolerated
Treatment with CDDO for 20 weeks was well tolerated
without evidence of any noticeable toxicity with respect
to animal appearance, behavior or change in the body
weight. Body weight increased as a function of age at
the same rate in both the vehicle control and treatment
group from 20 ± 0.8 g (control group) and 20.5 ± 0.9 g
(treatment group) at 5 weeks of age to 32.7 ± 1.5 g and
31.9 ± 1.9 g, respectively at 25 weeks of age.
Prostate and seminal vesicles by in vivo imaging
MR images were obtained before and after the start of
the treatment. The analysis of images showed similar
Figure 2 Measurement of signal intensity changes.
Representative images of seminal vesicles from a mouse showing
signal intensity on FATSAT T2-weighted image with a TE of 11 ms
(upper), with a TE of 70 ms (middle) and subtracted image
(lower). Note the differential signal intensity among different
tissues on higher TE. ROIs on lower image indicate the
representative areas from where signal intensity changes were
determined. M = muscles.
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0.03 cm
3 at 5 weeks) compared to that of treated (0.143
±0 . 0 7c m
3 at 5 weeks) at 5 weeks. However the volume
became significantly higher (p < 0.05) in control mice
(0.596 ± 0.17 cm
3 at 25 weeks) compared to that of
treated mice after 20 weeks following the start of the
treatment (0.397 ± 0.13 cm
3 at 25 weeks) (Figure 3A).
On the other hand, volumes of the prostate glands mea-
s u r e df r o m1 0a n i m a l si ne a c hg r o u pw e r en o td i f f e r e n t
among the control (0.02 ± 0.006 cm
3) and treated (0.02
± 0.005 cm
3) animals at 5 weeks. Increased volume of
prostate gland was observed in control animals (0.044 ±
0.019 cm
3 at 25 weeks) compared to that of treated ani-
mals (0.03 ± 0.018 cm
3 at 25 weeks), although signifi-
cant difference was not achieved (p = 0.102) (Figure 3B).
Similarly, weights of the prostate glands collected from
these same animals that underwent MRI also did not
show significant difference (p = 0.17) between the con-
trol (0.058 ± 0.014 gm at 25 weeks) and treated groups
(0.045 ± 0.019 gm at 25 weeks). The measured volume
of prostate glands was in agreement with the measured
weight determined during collection of tissues following
euthanasia (Figure 3C) when compared between con-
trols and treated animals (tendency to increase volume
and weight in control group).
Analysis of signal intensity
Similar changes in signal intensity in seminal vesicle
were observed in both groups of animals before starting
the treatment at the age of week 5. However, when the
signal intensity changes in seminal vesicles between the
control and treated animals were compared at 25 weeks,
significantly (p < 0.01) lower changes in signal intensity
were observed in treated animals (Figure 4A), indicating
less number of tumor foci to the seminal vesicles of
treated animals. Control animals showed significantly
higher changes in signal intensity in seminal vesicles at
25 weeks when compared with corresponding treated at
25 weeks (p < 0.001) and all animals at 5 weeks (p <
0.01). The MRI findings were also supported by histol-
ogy analysis of seminal vesicles from two groups of ani-
mals (Figure 4B).
CDDO slows down the progression of prostate carcinoma
in TRAMP mice
In mice treated with CDDO for 20 weeks, two of the
c o n t r o lm i c e( o u to f2 5 ,d i dn o tu n d e r g oM R I )s h o w e d
very large tumors originating from the prostate, whereas
none of the CDDO treated mice showed these large
tumors. In 7 out of 10 control mice (70%) tumor growth
was evident in seminal vesicles as opposed to 3 out of
10 CDDO-treated mice (30%). There was no significant
difference (p = 0.17) in the prostate gland weight when
compared between the treated and non-treated animals
that underwent MRI (n = 10 in each group). However,
significant difference was noticed when all animals (n =
25 in each group) were combined (CDDO = 0.040.9 ±
0.013 gm; Control = 0.073.2 ± 0.014 gm, p < 0.01). His-
tological evaluation of the DLP of control mice (that
underwent MRI) showed well-differentiated adenocarci-
noma in 8 of the 10 mice (80%), 2 mice showed moder-
ately differentiated CaP (20%), and none showed normal
tissue, PIN or high PIN, indicating that 100% of the
control mice had cancerous lesions in the DLP (Figure
5). In contrast, 1 CDDO treated mice (10%) had normal
DLP, another showed well-differentiated CaP (10%), and
8 mice (80%) had PIN or high PIN lesions (that under-
went MRI). These data demonstrated that majority of
the treated animals (90%) had noncancerous lesions ran-
ging from normal tissue to preneoplastic PIN and high
PIN compared to 100% of the control mice that showed
CaP in the DLP. CDDO also inhibited the progression
of prostate cancer into the ventral prostate.
Discussion
Although several murine prostate cancer models are
available (e.g., LADY transgenic mine, PTEN null,
MPAKT etc.), we used TRAMP mouse model in the
present study because it is the most well-characterized
and extensively used preclinical model of prostate
tumorigenesis in chemoprevention studies. Probasin
promoter directed expression of SV40 early genes in the
prostate epithelium drives the development of prostate
cancer in DLP and ventral prostate glands in an age-
dependent manner beginning with the emergence of
prostatic intraepithelial neoplasia (PIN), a preneoplastic
lesion by 6-8 weeks of age followed by high grade PIN
(HGPIN) by 10-12 weeks of age. Focal carcinoma devel-
ops between 12-18 weeks and poorly differentiated car-
cinoma is observed by the age of 18-24 weeks [17,18].
Tumor metastasizes to the liver, lungs, bone and pelvic
lymph nodes by 24-30 weeks of age [19]. The slow pro-
gression of the multistep process of prostatic tumorigen-
esis over a period of 8-30 weeks renders TRAMP model
highly suitable for exploiting the chemopreventive effi-
cacy of novel agents. Indeed, TRAMP mice have been
successfully used to evaluate the chemopreventive activ-
ity of several natural and synthetic compounds including
sulforaphane, green tea polyphenols, garlic constituents,
genistein etc. [13,20-23].
Most of the investigations that follow the progression
of prostate cancer in chemopreventive treatment strate-
gies use direct measuremento ft u m o rw e i g h t / s i z ea s
well as the weight of total genitourinary system as a
measure of tumor progression following euthanasia.
However, this method of measuring progression cannot
follow the same animals over the span of the treatment
duration. In vivo imaging modalities could be a great
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Page 6 of 11Figure 3 Measurement of seminal vesicles and prostate gland volume by MRI. (A) MR images show significantly increased volume of
seminal vesicles by 25 weeks in control animals compared to that of treated animals. Note the similar volume at the beginning of the
treatment (at 5 weeks). (B) Similar to seminal vesicles, prostate glands also showed higher volume in control animals on MRI which was also
confirmed at necropsy (C, although significant differences were not achieved). Note the similar volume at the beginning of the treatment (at 5
weeks).
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Page 7 of 11Figure 4 Changes in signal intensity and micro-tumor foci. (A) Changes in T2 signal intensity in seminal vesicles was significantly higher in
control animals at 25 weeks, which indicate heterogeneous tissues (involvement of micro-tumor foci) compared to that of treated animals at 25
weeks or of animals at 5 weeks. (B) Multiple tumor foci were observed in seminal vesicles of control animals (a, b, c, d) compared to that of
treated animals (e, f). a, b, e are with x10 and c, d, f are with x40 magnifications. Bars in all images represent 100µm.
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ment. In our previous study, we have shown the impor-
tance of FATSAT T2-weighted MRI sequence in
detecting prostate glands as well as orthotopic
implanted prostate cancer [24]. One advantage of MRI
is that the images of the prostate gland can be obtained
in all planes to identify the glands correctly or MRI can
be used to obtain 3D images to reformat later to see the
gland in all planes (currently we are optimizing 3D iso-
tropic image sequences). In the current study, we have
also used FATSAT sequence to detect the prostate
gland, although individual tumor was not detected
clearly. Inability to detect the tumor in prostate gland
could be due the model itself. TRAMP model produces
micro tumors both in prostate and seminal vesicles
unless it is in late stages of development. Histopathology
also confirmed the size of the tumors in the gland and
seminal vesicles. With the current hardware of 3T clini-
cal MRI system, it may not be possible to detect these
sub-millimeter size of prostate cancer by in vivo ima-
ging. We need to have either high strength dedicated
animal MRI system or imaging of animal in an ex vivo
setting. Other technique would be to use contrast
enhancement. We have not tried contrast enhancement
in this study, although we think contrast enhancement
may not give concrete results, knowing the size of the
tumors. However, our in vivo imaging method has pro-
duced comparable results to that of measured prostate
gland weight at necropsy. In that respect, our method of
in vivo imaging can be used to follow the chemopreven-
tive strategy in TRAMP model of mouse prostate
cancer.
Figure 5 HE staining of prostate gland. H&E-stained sections of DLP from representative cases of 25 week old vehicle control or CDDO-
treated TRAMP mouse. Control DLP showing well differentiated carcinoma and CDDO-treated DLP showing low-grade PIN. x25 magnifications.
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show the presence or absence of tumors in any tissues.
We have acquired the FATSAT T2-weighted images
using two echoes (11 ms and 70 ms). Lower TE T2-
weighted images usually indicate total density of the
proton in a tissue, which could be almost identical
throughout the tissue of interest, whereas high TE
images usually produce differential signal intensity from
a tissue/organ based on the differential relaxation or T2
parameters [25,26] (http://www.e-radiography.net/mrict/
fund mr2/fundmri 2.htm). It is expected that multiple
small tumor foci and associated edema will cause
lengthening of T2 values in seminal vesicles of control
untreated animals compared to that of treated animals,
therefore, signal intensity on T2-weighted images will
vary based on the echo delay time (TE). The TR used in
image acquisition is long enough to recover full longitu-
dinal magnetization between repetitions and the signal
intensity on MR images with different TE will be differ-
ent between areas of normal seminal vesicle and in
areas of tumor growths due to varying T2 values. By
subtracting high TE images from low TE images, we
could have a differential signal intensity patterns which
will be different between treated and control groups of
animals. Our image analysis proved our hypothesis and
there were significant differences in differential signal
intensity between the treated and control animals at 25
weeks. Our image analysis findings were also supported
by histopathology, where multiple microscopic tumor
foci were observed in seminal vesicles of control
animals.
Conclusion
In conclusion, our study demonstrated the differences in
the volumes of prostate gland and seminal vesicles in
TRAMP mice following chemoprevention strategy and
these changes can be detected by in vivo 3T clinical
MRI. In vivo MRI is helpful in assessing the chemopre-
vention of prostate cancer in TRAMP mice.
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